Cite
HARVARD Citation
Rubin, D. et al. (2022). Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials. Lancet gastroenterology and hepatology. pp. 17-27. [Online].